LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Wessel, Kristin M"
  2. AU="Wilson, Jenna M"
  3. AU="Goines, Paula"
  4. AU=Ippolito Mariachiara AU=Ippolito Mariachiara
  5. AU="Jose Chauca"
  6. AU="Asih, Puji B S"
  7. AU="Dsane-Selby, Lydia"
  8. AU="Tolossa, Tadesse"
  9. AU="Erdal Bedir"

Suchergebnis

Treffer 1 - 3 von insgesamt 3

Suchoptionen

  1. Artikel ; Online: Targeting tumor microenvironment and metastasis in children with solid tumors.

    Wessel, Kristin M / Kaplan, Rosandra N

    Current opinion in pediatrics

    2021  Band 34, Heft 1, Seite(n) 53–60

    Abstract: Purpose of review: The prognosis of pediatric patients with metastatic solid tumors remains poor, necessitating development of novel therapeutic strategies. The biology of the pediatric tumor microenvironment (TME) presents obstacles for the efficacy of ...

    Abstract Purpose of review: The prognosis of pediatric patients with metastatic solid tumors remains poor, necessitating development of novel therapeutic strategies. The biology of the pediatric tumor microenvironment (TME) presents obstacles for the efficacy of current therapeutic approaches including immunotherapies. Targeting various aspects of the TME in pediatric patients with solid tumors represents a therapeutic opportunity that may improve outcomes. Here we will discuss recent advances in characterization of the TME, and clinical advances in targeting the immune, vascular, and stromal aspects of the TME.
    Recent findings: Although immunotherapies have shown limited success in the treatment of pediatric solid tumor patients thus far, optimization of these approaches to overcome the TME shows promise. In addition, there is increasing focus on the myeloid compartment as a therapeutic target. Vascular endothelial growth factor (VEGF) targeting has resulted in responses in some refractory pediatric solid tumors. There has been relatively little focus on stromal targeting; however, emerging preclinical data are improving our understanding of underlying biology, paving the way for future therapies.
    Summary: Although translation of TME-targeting therapies for pediatric solid tumors is in the early stages, we are optimistic that continued exploration of approaches aimed at rebalancing the TME will lead to improved outcomes for this population.
    Mesh-Begriff(e) Child ; Humans ; Immunotherapy/methods ; Neoplasms/drug therapy ; Prognosis ; Tumor Microenvironment ; Vascular Endothelial Growth Factor A/therapeutic use
    Chemische Substanzen Vascular Endothelial Growth Factor A
    Sprache Englisch
    Erscheinungsdatum 2021-11-23
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, N.I.H., Intramural ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 1049374-8
    ISSN 1531-698X ; 1040-8703
    ISSN (online) 1531-698X
    ISSN 1040-8703
    DOI 10.1097/MOP.0000000000001082
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 3049: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: Adoptive Cell Therapy in Pediatric and Young Adult Solid Tumors: Current Status and Future Directions.

    Ligon, John A / Wessel, Kristin M / Shah, Nirali N / Glod, John

    Frontiers in immunology

    2022  Band 13, Seite(n) 846346

    Abstract: Advances from novel adoptive cellular therapies have yet to be fully realized for the treatment of children and young adults with solid tumors. This review discusses the strategies and preliminary results, including T-cell, NK-cell and myeloid cell-based ...

    Abstract Advances from novel adoptive cellular therapies have yet to be fully realized for the treatment of children and young adults with solid tumors. This review discusses the strategies and preliminary results, including T-cell, NK-cell and myeloid cell-based therapies. While each of these approaches have shown some early promise, there remain challenges. These include poor trafficking to the tumor as well as a hostile tumor microenvironment with numerous immunosuppressive mechanisms which result in exhaustion of cellular therapies. We then turn our attention to new strategies proposed to address these challenges including novel clinical trials that are ongoing and in development.
    Mesh-Begriff(e) Cell- and Tissue-Based Therapy ; Child ; Humans ; Immunotherapy, Adoptive/methods ; Neoplasms/therapy ; Receptors, Chimeric Antigen ; Tumor Microenvironment ; Young Adult
    Chemische Substanzen Receptors, Chimeric Antigen
    Sprache Englisch
    Erscheinungsdatum 2022-02-22
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article ; Research Support, N.I.H., Intramural ; Review
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2022.846346
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel ; Online: Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis.

    Kaczanowska, Sabina / Beury, Daniel W / Gopalan, Vishaka / Tycko, Arielle K / Qin, Haiying / Clements, Miranda E / Drake, Justin / Nwanze, Chiadika / Murgai, Meera / Rae, Zachary / Ju, Wei / Alexander, Katherine A / Kline, Jessica / Contreras, Cristina F / Wessel, Kristin M / Patel, Shil / Hannenhalli, Sridhar / Kelly, Michael C / Kaplan, Rosandra N

    Cell

    2021  Band 184, Heft 8, Seite(n) 2033–2052.e21

    Abstract: Metastasis is the leading cause of cancer-related deaths, and greater knowledge of the metastatic microenvironment is necessary to effectively target this process. Microenvironmental changes occur at distant sites prior to clinically detectable ... ...

    Abstract Metastasis is the leading cause of cancer-related deaths, and greater knowledge of the metastatic microenvironment is necessary to effectively target this process. Microenvironmental changes occur at distant sites prior to clinically detectable metastatic disease; however, the key niche regulatory signals during metastatic progression remain poorly characterized. Here, we identify a core immune suppression gene signature in pre-metastatic niche formation that is expressed predominantly by myeloid cells. We target this immune suppression program by utilizing genetically engineered myeloid cells (GEMys) to deliver IL-12 to modulate the metastatic microenvironment. Our data demonstrate that IL12-GEMy treatment reverses immune suppression in the pre-metastatic niche by activating antigen presentation and T cell activation, resulting in reduced metastatic and primary tumor burden and improved survival of tumor-bearing mice. We demonstrate that IL12-GEMys can functionally modulate the core program of immune suppression in the pre-metastatic niche to successfully rebalance the dysregulated metastatic microenvironment in cancer.
    Mesh-Begriff(e) Adaptive Immunity ; Animals ; Cell Line, Tumor ; Genetic Engineering ; Humans ; Immunosuppression Therapy ; Interleukin-12/genetics ; Interleukin-12/metabolism ; Lung/metabolism ; Lung Neoplasms/immunology ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Lymphocyte Activation ; Male ; Mice ; Mice, Inbred C57BL ; Mice, Transgenic ; Myeloid Cells/cytology ; Myeloid Cells/immunology ; Myeloid Cells/metabolism ; Neoplasm Metastasis ; Rhabdomyosarcoma/metabolism ; Rhabdomyosarcoma/pathology ; Survival Rate ; T-Lymphocytes/immunology ; T-Lymphocytes/metabolism ; Tumor Microenvironment
    Chemische Substanzen Interleukin-12 (187348-17-0)
    Sprache Englisch
    Erscheinungsdatum 2021-03-24
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, N.I.H., Intramural
    ZDB-ID 187009-9
    ISSN 1097-4172 ; 0092-8674
    ISSN (online) 1097-4172
    ISSN 0092-8674
    DOI 10.1016/j.cell.2021.02.048
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1167: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 58: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang